Eugia Pharma Receives USFDA Approval for Nicardipine HCl Injection 25 mg/10 mL Single-Dose Vials

Eugia Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Nicardipine HCl Injection 25 mg/10 mL Single-Dose Vials.

Indications for this product include:

• Short-term treatment of hypertension when oral therapy is not feasible or not desirable.

Refer to package insert for full prescribing information.